Table 1. Incidence of hypertension after treatment with representative anti-angiogenetic agents.

Agents	Hypertension (%)
Monoclonal antibody-based tyrosine kinase inhibitors
bevacizumab	23.6
ado-trastuzumab emtansine	5.1
Small molecular tyrosine kinase inhibitors
sorafenib	15.3
sunitinib	21.6
axitinib	40.1
regorafenib	44.4
lenvatinib	67.8
pasopanib	42.0
vandetanib	24.2
mTOR (mammalian target of rapamycin) inhibitors
everolimus	4–13
temsirolimus	7

Quoted from the following articles:

(01) Yeh ET, et al, JACC 2009; 53: 2231–2247.

(10) Zamorano Jl, et al, Eur Heart J.2016; 37 (36): 2768–2801.

(11) Moudgil R, et al. Can J Cardiol 2016; 32: 863–870.

(12) Wang Z, et al. Eur J Clin Pharmacol 2014; 70: 225–231

(13) Schlumberger M, et al. N Engl J Med 2015; 372: 621–630.